原发性肝癌患者尿中环—磷酸鸟苷(cGMP)水平的进一步观察

The Further Observation on Level of Cyclic GMP in Urine in Primary Hepatocellular Carcinoma

我们前已报道原发性肝癌患者尿中cGMP的水平较正常人组明显升高,cAMP/cGMP值较正常人组明显下降,而cAMP值则无明显变化,本研究的目的是在此基础上进一步观察原发性肝癌患者尿中cGMP水平的变化规律,以探讨能否反映不同型的原发性肝癌;cGMP水平的增高是否为原发性肝癌所特有;进而评价测定尿中cGMP水平对原发性肝癌的临床意义。为此,我们对有无肝硬化并发和不同临床分型,分期的原发性肝癌患者尿中cGMP进行测定,同时也测定了肝硬化,白血病和其他一些恶性肿瘤患者尿中cGMP水平,现将初步结果报告。

Urinary cyclic GMP were determied in 50 cases of primary hepatocell-ular carcinoma, 15 cases of cirrhosis of liver, 14 cases of acute leukemia,3 cases of esophagus cancer and 1 case of lung cancer, and compared with those in 53 normal subjects. We found that the mean values of urinary cyclic GMP/creatinine ratios increased prominently (P<0.01 ) in the group of primary hepatocellular carcinoma, whether the primary hepatocelular carcinoma is complicated by cirrhosis or not, no matter what different clinical types, or stage Ⅱ or Ⅲ. The mean values for urinary cyclic GMP/creatinine ratios also increased prominently ( P<0.01 ) in the group of cirrhosis of liver, and the mean values for urinary cyclic GMP/creatinine ratios also increased ( P<0.05 ) in the group of acute, leukemia, but the mean values for urinary cyclic GMP/creatinine ratios among the groups hare no signi ficant difference. We thought that the increase in urine cyclic GMP in primary hepatocellular carcinoma is not characteristic, it might represent a proliferative change of cancer cell, the determination of urinary cyclic GMP levels does not help the diagnosis of the primary hepatocellular carcinoma.